EP1648532A1 - Multifunktionales implantat - Google Patents
Multifunktionales implantatInfo
- Publication number
- EP1648532A1 EP1648532A1 EP04742264A EP04742264A EP1648532A1 EP 1648532 A1 EP1648532 A1 EP 1648532A1 EP 04742264 A EP04742264 A EP 04742264A EP 04742264 A EP04742264 A EP 04742264A EP 1648532 A1 EP1648532 A1 EP 1648532A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bone
- implant device
- matrix
- implant
- osteoconductive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the present invention relates generally to the treatment of disorders of skeletal tissue, to its regeneration and remodeling, and specifically, to devices and methods for inhibiting bone resorption and improving bone formation, in the form of fixation devices or supporting a prosthetic implant.
- the basis of enhancing bone repair and regeneration is based principally on the use of 1) implant materials, 2) osteoinductive molecules, 3) osteoconductive particles or materials such as bone grafts, and ceramics such as HA, TCP or bioactive glass, etc. Since successful bone repair and regeneration involves various stages where biological and biomechanical factors interact to bring about the ultimate result of bone union, many factors in this complex interplay have to be addressed. Successful bone repair in some pathological conditions or in situations where bone healing may be delayed due to factors such as age, disease or drugs, are more challenging.
- metallic materials afford the highest mechanical properties necessary for use as skeletal prosthetic implants but they are much more rigid than the bone itself with the risk of stress shielding, osteopenia, weakening of the bone and risk of fracture or loosening.
- metals include, titanium and titanium alloy, stainless steel, gold, cobalt-chromium alloys, tungsten, tantalum, as well as similar alloys.
- Titanium is popular in the implant field because of its said superior corrosion resistance, biocompatibility, and physical and mechanical properties compared to other metals.
- recently some particles of titanium have been found in lymph nodes, and thus a search for a better material or radical change in the way that addresses the problem of treatment of bone needs to be developed.
- a significant drawback to titanium implants is the tendency to loosen over time.
- Bone itself is not a static but a dynamic tissue that undergoes turnover and remodeling. Bone is a living tissue whose cells interact with the biomechanical factors to adjust itself into a right remodeling line where either bone formation or bone resorption is the ultimate result in defined area at defined point in time. Even a well-suited implant at the time of surgery (using the principles of carpentry), such an implant can be found to be loosed after some time because of bone resorption. Thus, there is a clear need to address the implant-bone interface in a dynamic scale that involves both the implant and the tissue and timeframe.
- Osteointegration is defined as bone growth directly adjacent to an implant without an intermediate fibrous tissue layer. This type of fixation avoids many complications associated with adhesives and theoretically would result in the strongest possible implant-to-bone bond.
- One common method is to roughen a metal surface creating a micro or macro-porous structure through which bone may attach or grow.
- Implant device designs have been created attempting to produce a textured metal surface that will allow direct bone attachment. US Patents 5,609,635 and 5,658,333 are a couple of examples of these devices.
- HA hydroxyapatite
- beta-TCP beta-tricalcium phosphate
- the HA coatings increase the mean interface strength of titanium implants (see Cook et al., Clin. Ortho. Rel. Res., 232, p. 225, 1988), rapid bone growth and increased osteointegration (see Sakkers et. al., J. Biomed. Mater. Res., 26, p. 265, 1997).
- Optimal HA coating thickness ranges from 50-100 microns (see Thomas, Orthopedics, 17, p. 267-278, 1994).
- Osteoinductive proteins are signaling molecules that stimulate new bone production. These proteins include PDGF, IGF-I, IGF-II, FGF, TGF-beta and associated family members.
- the most effective bone formation-inducing factors are the bone morphogenetic proteins (BMPs).
- the BMPs represent a TGF-beta super-family subset. Over 15 different BMPs have been identified. Most members of this TGF-beta subfamily stimulate the cascade of events that lead to new bone formation (for example U.S. Pat. Nos. 5,652,118; and 5,714,589, reviewed in J. Bone Min. Res., 1993, v8, suppl-2, p. s565-s572). These processes include stimulating mesenchymal cell migration, osteoconductive matrix disposition, osteoprogenitor cell proliferation and differentiation into bone producing cells. Effort, therefore, has focused on BMP proteins because of their central role in bone growth and their known ability to produce bone growth next to implants e.g.titanium (see Cole et. al., Clin.
- a method for the design of a spinal fusion device comprised of wire mesh infused with osteoinductive molecules.
- This device is intended solely for use in spinal fusions and is not designed for use with other prosthetic implants intended for use in other body areas. It is also not designed to be attached to orthopedic implants.
- the goal is for selective beneficial effects on the target, in this case bone cells.
- effective therapies will be those that stimulate osteoblast accumulation, proliferation and differentiation.
- growth regulatory factors in bone including fibroblast growth factor-l (FGF-I), IGF-I and -II, BMPs, TGF ⁇ and PDGF.
- osteoconductive factors are those that create a favorable environment for new bone growth, most commonly by providing a scaffold for bone ingrowth.
- the clearest example of an osteoconductive factor is the extracellular matrix protein, collagen.
- examples of other important osteoconductive materials are also the ceramics such as HA, TCP and bioactive glass.
- Antr-osteolytic bisphosphonates administered orally have the problem of poor GIT absorption and need for higher doses. Gl upset the most common complaint seen with bisphosphonates.
- esophagitis was a potentially serious side effect that occurs in a small percentage of patients.
- 475,000 patients had been treated with alendronate; 1,213 adverse reports had been received and, of these, 199 had adverse effects related to the esophagus.
- the side-effects were rated as serious or severe (de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate.
- Alendronate is contraindicated in patients with abnormalities of the esophagus that delay esophageal emptying, such as stricture or achalasia (de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996; 335: 1016-1021).
- These problems thus present a limitation on the use of bisphosphonates according to this mode of therapy and to a certain extent where local problem is addressed, there is a clear need to accomplish the drug delivery locally (to avoid Gl problems).
- US patent 6214049 shows a fibrillar metal wire (e.g. of titanium) attached to a prosthetic device core and which can be coated with biodegradable polymer, which may contain various osteoconductive and osteoinductive factors.
- Osteoclast inhibitors such as bisphosphonate are mentioned as one example.
- DBM demineralized bone matrix
- the DBM composition may also be used as a drug delivery device and it may contain bisphosphonates for this purpose.
- the agent to be delivered is absorbed or otherwise associated with the DBM itself and the role of the polymer is to act as barrier.
- Bone tissue itself is a composite material made up of fibers of collagen running through hydroxyapatite, Ca 5 (P0 4 ) 3 OH. Hydroxyapatite constitutes about 70% of bone tissue. However HA itself is not resorbable and may lead to fibrous tissue formation. ⁇ -TCP & absorbable bioactive glass may be better alternatives.
- matrices have been developed to contain and release bioactive peptides for osteo-induction, bone morphogenetic protein- molecules, as the matrix degrades.
- Organic polymers such as polylactides, polyglycolides, polyanhydrides, and polyorthoesters, which readily hydrolyze in the body into inert monomers, have been used as matrices (see U.S. Pat. Nos. 4,563,489; 5,629,009; and 4,526,909).
- the efficiency of BMP-release from polymer matrices depends on the matrices resorption rate, density, and pore size. Monomer type and their relative ratios in the matrix influence these characteristics.
- Polylactic and polyglycolic acid copolymers, BMP sequestering agents, and osteoinductive factors provide the necessary qualities for a BMP delivery system (see U.S. Pat. No. 5,597,897).
- Alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer, and poly (vinyl alcohol) are additional polymer examples that optimize BMP-bone-growth-induction by temporally sequestering the growth factors (see U.S. Pat. No. 5,597,897).
- this approach adds only one factor in bone formation/bone resorption balancing process.
- collagen serves as the natural carrier for BMPs and in a way as an osteoconductive scaffold for bone formation.
- Demineralized bone in which the main components are collagen and BMPs has been used successfully as a bone graft material (see U.S. Pat. No. 5,236,456).
- Proper implant load distribution is yet another characteristic important for correct prosthetic function, such as described for example in U.S. patents Nos.. 5,639,237, and 5,360,446.
- U.S. Pat. No. 5,458,653 describes a prosthetic device coated with a bioabsorbable polymer in specific implant regions to, theoretically, better distribute the load placed upon it.
- Many other endosseous dental implants with shapes attempting to distribute load including helical wires, tripods, screws and hollow baskets have also been used. The clinical success of all these implant types is dependent on placement site, implant fit and the extent of fibrous tissue formation around the implant preventing direct bone contact.
- a method and apparatus for bone tissue management in a mammalian body is presented.
- a primary application of the present invention is to fix fractures and osteotomies, and support a prosthetic multifunctional implant device.
- the implant device comprises a biocompatible bioresorbable polymer as a matrix, a reinforcing biocompatible and bioresorbable structure in close association with said matrix, and at least an anti-osteolytic agent in said matrix.
- the mechanical strength of the implant device can be achieved by the use of self-reinforcement technique or other reinforcing technique.
- the present invention provides a method and a structure for achieving durable bone formation that has a better quality in terms of bone structure, mineral density and function (strength).
- the present invention provides a novel way to augment bone formation for a variety of applications in bone management.
- the implant can comprise: 1) a biocompatible bioresorbable polymer forming a matrix 2) osteoinductive and/or osteroinductive material in said matrix, and 3) an antiosteolytic agent in said matrix.
- one or more molecules that function as nutrients, blood-clotting factors, angiogenic factors, or trace elements, can be included in the matrix.
- the matrix is in close association with a reinforcing structure made of biocompatible bioresorbable polymer, either of the same material or of different material in view of chemical composition.
- the matrix may be the reinforcing structure itself, where the increased strength compared with the raw material is created by means of manufacturing technique, for example orientation and fibrillation of the polymer material so that nearly the whole mass of material has been oriented in desired way (e.g. U.S. Patent No. 4,968,317).
- the term matrix is understood as material capable of incorporating various substances, e.g. active agents such as antiostelytic agents and osteoinductive and/or osteoconductive material, and acting as carrier for them.
- the reinforcing structure and the matrix exist as discrete areas in the implant device, the reinforcing structure possesses greater strength than the matrix, which may be due to different chemical composition, or different physical structure if the chemical composition is the same.
- the reinforcing portion can exist inside the matrix as discrete areas, such as elongate fibers, which may be different in composition or created by self-reinforcing technique form the same material as the matrix. Suitable self-reinforcing techniques creating areas of different physical properties starting from the same raw material within the implant device are good examples of the latter alternative.
- the matrix can further exist as a coating in an implant device where the core is formed of biocompatible bioresorbable polymer material and acts as the reinforcing portion.
- the matrix can also be associated with the implant device as a separate piece, e.g. it may be wrapped around a resorbable implant device as a filament, mesh, sheet, or the like.
- the piece need not necessarily have a reinforcing portion, because the implant device itself imparts strength to the combination, and the separate piece comprises matrix and the antiosteolytic agent.
- the implant may comprise an osteoinductive-protein- sequestering agent comprising monomeric and polymeric units of hyaluronic acid, alginate, ethylene glycol, polyoxyethylene oxide, carboxyvinyl polymer, and vinyl alcohol.
- the agent can be also the polymers collagen or chitosan.
- the polymer may also be composed of a composite of synthetic or naturally occurring polymers comprising collagen and glycosaminoglycan. These materials act as carriers for the osteoinductive proteins and can be in the form of coating on the implant body or filled in pores, openings or channels in the body, which is an advantageous way of incorporating thermally sensitive proteins to the implant device.
- the efficiency of the above-described multifunctional therapy may also be increased and the supplement of the therapy to the area where it is needed to act at, such as around implants sites of metastasis, osteolysis or for fixation of bones can be achieved.
- Fig. 1 shows a first embodiment of the form of the implant device according to the invention
- Fig. 2 shows a second embodiment of the form
- Fig. 3 shows a third embodiment of the form
- Fig. 4 shows one embodiment of the relationship between the matrix and reinforcement
- Fig. 5 shows a second embodiment of the relationship
- Fig. 6 shows a third embodiment of the relationship
- Fig. 7 shows a fourth embodiment
- Fig. 8 shows a fifth embodiment.
- the implant device of the invention has at least the following components:
- Matrix polymer The matrix polymer is biocompatible and bioresorbale and acts as carrier for various agents and materials that contribute to the multifunctionality of the implant.
- Resorbable polymers that can be used are listed e.g. in table 1 of U.S. Patent No. 4,968,317, the disclosure of which is incorporated herein by reference, and those listed in table 1 of European patent 442911 , the disclosure of which is incorporated herein by reference.
- the resorbabe polymers include the following:
- PLA Poly-L-lactide
- PDLA Poly-D-lactide
- PDLLA Poly-DL-lactide
- L-lactide/DL-lactide copolymers L-lactide/D-lactide copolymers Copolymers of PLA 8. Lactide/tetramethylene glvcolide copolymers 9. Lactide/trimethylene carbonate copolymers 10. Lactide/ ⁇ -valerolactone copolymers 11. Lactide/ ⁇ -caprolactone copolymers 12. Polydepsipeptides (glycine-DL-lactide copolymer) 13. PLA/ethylene oxide copolymers
- Matrix polymer is in close association with a reinforcing structure that contributes to the strength of the implant device, which is an important factor in bone fixation and other similar applications.
- a special case is the function of the matrix both as the carrier material and reinforcing structure, due to self-reinforcing technique during the manufacture of the implant device.
- Such techniques are based on mechanical modification of the polymeric raw material, and may include orientation and fibrillation of partly crystalline materials according to above- mentioned U.S. Patent 4,968,317, or mechanical modification of entirely amorphous materials by molecular orientation of the material, according to U.S. Patent 6,503,278, the disclosure of which is incorporated herein by reference.
- the reinforcing structure may be of the same chemical composition as the matrix and be embedded in the same.
- An example of such a composite structure is disclosed e.g. in U.S. Patent No. 4,743,257, the disclosure of which is incorporated herein by reference.
- This structure is also termed "self-reinforced" because of the common origin of both matrix and the reinforcing structure.
- the discrete areas of matrix and reinforcing structure can be 5 composed of chemically different polymers, both being biocompatible and bioresorbable, and the polymer of the reinforcing structure being selected because of its mechanical properties (strength).
- the reinforcing structure can be bioabsorbable0 inorganic materials, for example in the form of fibers of bioabsorbable bioactive glass, as described in U.S. Patent No. 6,406,498, the disclosure of which is incorporated herein by reference.
- the bioactive glass may serve at the same time as osteoconductive material.5
- the reinforcing structure can be the mass of the implant body having a coating which consists of matrix polymer. This matrix polymer acts as carrier for the above-mentioned active agents and materials. It is possible that the body of the implant device is of different0 bioresorbable material and is itself reinforced by some of the above- mentioned techniques.
- the matrix polymer of the coating can be in this case chitosan (a derivative of chitin) for example.
- the matrix polymer acting as carrier can be, alternatively to or additionally to being in the form of coating, filled in pores, channels or openings of the implant5 body.
- the reinforcing structure may be an implant body on which the matrix polymer containing the above-mentioned active agents is fitted as a separate material piece, for example by winding, wrapping etc.0
- the matrix may be in this case a filament, mesh, sheet, or the like, relatively flexible construction.
- the structure of the implant body may be reinforced by any technique discussed above.
- Bisphosphonates are structural analogs of pyrophosphates. They have a pharmacologic activity specific for bone, due to the strong chemical affinity of bisphosphonates for hydroxyapatite, a major inorganic component of bone (see also Watts WB:Bisphosphonates therapy for postmenopausal osteoporosis. South Med J. 1992;85(Suppl):2-31 ).
- Bisphosphonates have the following general formula:
- Substitution of different side chains for hydrogen at locations R ⁇ and R 2 changes the in vitro potency and side effect profile of the compound.
- Short alkyl or halide side chains e.g., etidronate, clodronate characterize first generation bisphosphonates.
- Second generation bisphosphonates include aminobisphosphonates with an amino- terminal group (e.g., alendronate and pamidronate).
- Tiludronate has a cyclic side chain, not an amino terminal group, but is generally classified as a second-generation compound based on its time of development and potency.
- Third generation bisphosphonates have cyclic side chains (e.g., risedronate, ibandronate, zoledronate).
- bisphosphonates include incardronate (cimadronate), olpadronate, piridronate, minodronate, neridronate, EB-1053 and YH529.
- bisphosphonate includes acids, salts, esters, hydrates and other solvates.
- Any bisphosphonate mentioned above can be used in the matrix 5 polymer. It is also possible that two or more different types of bisphosphonates are used in the same implant device.
- the osteoconductive material that is used in the implant device can be any factor known to create a favorable environment for new bone growth, most commonly by providing a scaffold for bone ingrowth.
- the osteoconductive factors that can be used is the extracellular matrix protein, collagen. Examples of other important osteoconductive factors
- HA hydroxyapatite
- TCP beta- tricalcium phosphate
- bone graft autogenic, allogenic or xenogenic bone graft
- the osteoinductive material that is used in the implant device can be any osteoinductive protein that is known to stimulate new bone production. These proteins include PDGF, IGF-I, IGF-II, FGF, TGF- 25 beta and associated family members. The most effective bone formation-inducing factors are the bone morphogenetic proteins (BMPs). Angiogenic factors such as VEGF, PDGF, FGF etc. can also be incorporated to enhance / maintain bone formation process where suitable.
- BMPs bone morphogenetic proteins
- Angiogenic factors such as VEGF, PDGF, FGF etc. can also be incorporated to enhance / maintain bone formation process where suitable.
- Implant device can take any form known in surgery in connection with bone repair and healing (fixation, regeneration/generation, augmentation). It can be in the form of screw, nail, pin, bolt, plate, rod, mesh, scaffold or filament or some combination of the above structures, in general any stiff or tough structure having sufficient strength over the required period of time after being placed in contact with a bone. It can be shapeable to desired form by bending (for example a plate) to fit the site during the operation, or flexible but of sufficient tensile strength, such as a filament. Further, the device can have a closed surface or certain porosity or holes passing through.
- Fig. 1 shows a generally rod-shaped implant device, whose special shapes are screw and nail, which can be used as fixation devices for example.
- Fig. 2 shows a plate-shaped implant device.
- Fig. 3 shows a filament, of which a mesh (here in the form of woven fabric), or a thread or cord (shown in cross-section) can be formed.
- Fig. 4 shows a device where discrete reinforcing elements are embedded in the matrix.
- Fig. 5 shows a device in cross-section where a coating of matrix polymer exists on the implant body.
- Fig. 6 shows the alternative where channels inside an implant body are filled with matrix polymer. The same idea applies to implants where the body comprises pores or openings, which do not necessarily pass through the whole body.
- Fig. 7 shows the alternative where a matrix polymer is between filaments in a bundle (the polymer may also surround the bundle as a coating).
- Fig. 8 shows the alternative where a flexible structure comprising the matrix polymer is wrapped around an
- the antiosteolytic agent can be in the matrix polymer in the coating, in the matrix polymer filling the channels, pores or openings, or in the matrix polymer between or around the filaments.
- the rest of the implant (the body or the filaments) is of another biocompatible bioresorbable material, preferably of another biocompatible bioresorbable polymer, which in turn may or may not contain reinforcing elements or areas, or may or may not be self-reinforced.
- the rest of implant may contain another active agent.
- the anti-osteolytic agent can also be in the rest of the implant, in which case this portion is of biocompatible bioresorbable polymer, which in turn contains reinforcing elements or areas, or is self-reinforced.
- the coating (Fig. 5) or the filling material (Fig. 6 or 7) may contain another active agent.
- the implant device in one embodiment may have a composite of mesh and stem, where the stem can have the anti-osteolytic agent in a matrix.
- a composite is a joint prosthesis, which is disclosed in U.S. Patent No. 6,113,640, where the fixation parts serving to fix the prosthesis to the bone could have the antiosteolytic agent.
- osteoconductive and/or osteoinductive material need not necessarily be in the same matrix as the antiosteolytic agent, but they can be in another matrix phase but in the same implant device.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20031120A FI20031120A0 (fi) | 2003-07-31 | 2003-07-31 | Monifunktionaalinen implanttilaite |
PCT/FI2004/050115 WO2005009496A1 (en) | 2003-07-31 | 2004-07-30 | Multifunctional implant device |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1648532A1 true EP1648532A1 (de) | 2006-04-26 |
EP1648532B1 EP1648532B1 (de) | 2009-12-09 |
Family
ID=27636145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04742264A Expired - Lifetime EP1648532B1 (de) | 2003-07-31 | 2004-07-30 | Multifunktionales implantat |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070191851A1 (de) |
EP (1) | EP1648532B1 (de) |
AT (1) | ATE451129T1 (de) |
DE (1) | DE602004024537D1 (de) |
FI (1) | FI20031120A0 (de) |
WO (1) | WO2005009496A1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458162B1 (en) | 1999-08-13 | 2002-10-01 | Vita Special Purpose Corporation | Composite shaped bodies and methods for their production and use |
US9220595B2 (en) | 2004-06-23 | 2015-12-29 | Orthovita, Inc. | Shapeable bone graft substitute and instruments for delivery thereof |
US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
EP1951327A2 (de) | 2005-11-17 | 2008-08-06 | Biomimetic Therapeutics, Inc. | Kiefer- und gesichtsknochenerweiterung mithilfe von rhpdgf-bb und einer biokompatiblen matrix |
WO2007092622A2 (en) | 2006-02-09 | 2007-08-16 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating bone |
JP5450063B2 (ja) * | 2006-06-29 | 2014-03-26 | オーソヴィータ・インコーポレーテッド | 生体活性骨移植片代替物 |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
JP5484047B2 (ja) | 2006-06-30 | 2014-05-07 | バイオミメティック セラピューティクス, エルエルシー | 回旋筋腱板傷害を処置するためのpdgf−生体マトリックス組成物および方法 |
EP2086598B1 (de) | 2006-11-03 | 2015-05-27 | BioMimetic Therapeutics, LLC | Zusammensetzungen und verfahren für behandlungen von arthrodese |
US20080195476A1 (en) * | 2007-02-09 | 2008-08-14 | Marchese Michael A | Abandonment remarketing system |
US20100172953A1 (en) * | 2007-06-13 | 2010-07-08 | Fmc Corporation | Biopolymer Based Implantable Degradable Devices |
CN102014977B (zh) | 2008-02-07 | 2015-09-02 | 生物模拟治疗有限责任公司 | 用于牵引成骨术的组合物和方法 |
BRPI0918611B8 (pt) | 2008-09-09 | 2021-06-22 | Biomimetic Therapeutics Inc | composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit |
WO2010036567A2 (en) * | 2008-09-25 | 2010-04-01 | Osteogenex Inc. | Harmine compounds for promoting bone growth |
US8882740B2 (en) | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
CN107080834A (zh) | 2010-02-22 | 2017-08-22 | 生物模拟治疗有限责任公司 | 用于治疗腱病的血小板衍生生长因子组合物和方法 |
US8617240B2 (en) | 2010-11-17 | 2013-12-31 | Charles D. Hightower | Moldable cushion for implants |
US8551525B2 (en) | 2010-12-23 | 2013-10-08 | Biostructures, Llc | Bone graft materials and methods |
FR2994097B1 (fr) | 2012-08-02 | 2015-08-21 | Teknimed | Dispositif resorbable et radio-opaque pour la fixation osseuse |
CN105120863B (zh) | 2013-03-14 | 2021-06-04 | 奥斯特克有限公司 | 促进骨生长的烷基胺骆驼蓬碱衍生物 |
KR101790782B1 (ko) | 2015-06-18 | 2017-10-26 | (주)다림티센 | 비스포스포네이트를 포함하는 콜라겐 기반의 서방형 bmp 전달체 및 이의 제조방법 |
CN107536659B (zh) * | 2017-08-23 | 2019-09-17 | 湖南碳康生物科技有限公司 | 一种一体化碳纤维复合材料人工骨及其制备方法 |
AU2019320773A1 (en) | 2018-08-14 | 2021-03-04 | Osteoqc Inc. | Fluoro β-carboline compounds |
SG11202101151SA (en) | 2018-08-14 | 2021-03-30 | Osteoqc Inc | Pyrrolo - dipyridine compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1210138A4 (de) * | 1999-04-22 | 2003-05-07 | Hydro Med Sciences Inc | Kontrollierte verabreichung von bisphosphonaten |
US6579533B1 (en) * | 1999-11-30 | 2003-06-17 | Bioasborbable Concepts, Ltd. | Bioabsorbable drug delivery system for local treatment and prevention of infections |
US20030055511A1 (en) * | 2000-03-03 | 2003-03-20 | Schryver Jeffrey E. | Shaped particle comprised of bone material and method of making the particle |
AUPR553701A0 (en) * | 2001-06-07 | 2001-07-12 | Royal Alexandra Hospital For Children, The | A device for the delivery of a drug to a fractured bone |
AU2002365969A1 (en) * | 2001-11-20 | 2003-06-10 | Scott Bruder | Flowable osteogenic and chondrogenic compositions |
-
2003
- 2003-07-31 FI FI20031120A patent/FI20031120A0/fi not_active Application Discontinuation
-
2004
- 2004-07-30 EP EP04742264A patent/EP1648532B1/de not_active Expired - Lifetime
- 2004-07-30 US US10/566,863 patent/US20070191851A1/en not_active Abandoned
- 2004-07-30 DE DE602004024537T patent/DE602004024537D1/de not_active Expired - Lifetime
- 2004-07-30 WO PCT/FI2004/050115 patent/WO2005009496A1/en active Application Filing
- 2004-07-30 AT AT04742264T patent/ATE451129T1/de not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO2005009496A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005009496A1 (en) | 2005-02-03 |
DE602004024537D1 (de) | 2010-01-21 |
FI20031120A0 (fi) | 2003-07-31 |
ATE451129T1 (de) | 2009-12-15 |
US20070191851A1 (en) | 2007-08-16 |
EP1648532B1 (de) | 2009-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1648532B1 (de) | Multifunktionales implantat | |
US6461385B1 (en) | Method and apparatus for augmenting osteointegration of prosthetic implant devices | |
Hu et al. | Bioinspired surface modification of orthopedic implants for bone tissue engineering | |
Frenkel et al. | Osseointegration on metallic implant surfaces: effects of microgeometry and growth factor treatment | |
P Pawar et al. | Biomedical applications of poly (lactic acid) | |
Lickorish et al. | A three-phase, fully resorbable, polyester/calcium phosphate scaffold for bone tissue engineering: Evolution of scaffold design | |
JP6212586B2 (ja) | 歯科補綴のための骨移植およびバイオ複合材料 | |
Thomas et al. | Calcium sulfate: Properties and clinical applications | |
Athanasiou et al. | Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers | |
Van der Elst et al. | Bone tissue response to biodegradable polymers used for intra medullary fracture fixation: a long-term in vivo study in sheep femora | |
Wang et al. | Titanium alloys in orthopaedics | |
Wu et al. | The effect of a slow mode of BMP-2 delivery on the inflammatory response provoked by bone-defect-filling polymeric scaffolds | |
Grzeskowiak et al. | Bone and cartilage interfaces with orthopedic implants: a literature review | |
Aunoble et al. | Biological performance of a new β‐TCP/PLLA composite material for applications in spine surgery: In vitro and in vivo studies | |
US8101198B2 (en) | Osteogenic enhancer composition | |
Alenezi et al. | Effects of local drug and chemical compound delivery on bone regeneration around dental implants in animal models: a systematic review and meta-analysis. | |
Tielinen et al. | The effect of transforming growth factor-β1, released from a bioabsorbable self-reinforced polylactide pin, on a bone defect | |
US7244445B2 (en) | Conformable, absorbable, solid composite preforms and their use for bone tissue engineering | |
WO2021087479A1 (en) | Composite filament for 3d printing of resorbable bone scaffolds | |
Agrawal | Biodegradable polymers for orthopaedic applications | |
Olivera et al. | Bone substitutes in orthopedic and trauma surgery | |
Erkin et al. | Biodegradable hard tissue implants | |
Katz et al. | Orthopedic biomaterials | |
Zeng | Application of poly (trimethylene carbonate) and calcium phosphate composite biomaterials in oral and maxillofacial surgery | |
Pina et al. | 5. Bioresorbable composites for bone repair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060207 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20070122 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ASHAMMAKHI, NUREDDIN Inventor name: TOERMAELAE, PERTTI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TOERMAELAE, PERTTI Inventor name: ASHAMMAKHI, NUREDDIN |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602004024537 Country of ref document: DE Date of ref document: 20100121 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20091209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100409 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100309 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100320 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100310 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 |
|
26N | No opposition filed |
Effective date: 20100910 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100731 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100731 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100730 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20110812 Year of fee payment: 8 Ref country code: FI Payment date: 20110722 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100730 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100610 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091209 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20130329 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120730 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120731 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20170721 Year of fee payment: 14 Ref country code: DE Payment date: 20170721 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602004024537 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20180730 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180730 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190201 |